AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04954690 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT05460962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing excercises
Description: Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
Study NCT05936892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity aerobic training
Description: upper extremity aerobic training \& baseline treatment will be given. Overall session time will be 40-45 minutes
Study NCT05936892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity resistance training
Description: upper extremity resistance training Overall session time will be 40-45 minutes
Study NCT05818306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-001
Description: Live biological product BL-001
Study NCT05818306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05553431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Description: Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
Study NCT05295472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grapholearn
Description: GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
Study NCT06557382 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive tests and reading-related evaluations
Description: Tests assessing cognitive status and reading were administered. (Frankfurter; MVPT-3, TILLs; etc.)
Study NCT05295472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vector
Description: A computer game focusing on children's development of mathematic skills
Study NCT05295472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual schooling
Description: No GL or Math computer games, only the usual schooling
Study NCT04746248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient labor induction
Description: The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
Study NCT04746248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient labor induction
Description: The participants are induced following standard inpatient care
Study NCT06556134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Iron Sucrose
Description: Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months
Study NCT06556134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid
Study NCT05388487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 45 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study NCT06534684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
Study NCT06534684 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
Study NCT05388487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 90 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study NCT05388487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 120 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study NCT05388487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 160 mg/m²
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study NCT05388487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16 /Arm 120 mg or 180 mg
Description: HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
Study NCT05007704 — intervention group
Intervention type: BEHAVIORAL
Intervention: Global Experts Consensus opinion using Delphi Methodology
Description: The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
Study NCT05195840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Treatment for Eating Disorders
Description: The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
Study NCT05195840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Eating Disorders
Description: The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
Study NCT05070195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral
Study NCT05070195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam Maleate, tablet, oral
Study NCT05348421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FTPB
Description: A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
Study NCT05348421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block
Description: A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
Study NCT05901558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies for Toddler ASD with Remote-therapy (STAR)
Description: The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
Study NCT05901558 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community intervention
Description: Regular community intervention
Study NCT05130060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer Peptide Vaccine PolyPEPI1018
Description: Given SC
Study NCT05130060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT06555523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided injection
Description: The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging
Study NCT06555523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded injection
Description: The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
Study NCT05880732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
Study NCT05880732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline isotonic solution
Description: only 250 ml of normal saline isotonic solution 30 minutes before induction,
Study NCT05190666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE Weight Loss program
Description: 12 month phone-based behavioral weight loss program
Study NCT05190666 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Chronic Disease Self-Management
Description: 12 month phone-based chronic disease self-management program
Study NCT05810480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polyreactive immunoglobulin G
Description: Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
Study NCT06556303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure
Study NCT06313138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Individual and Family Enhancement Program
Description: The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
Study NCT06313138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The Individual and Family Enhancement Program
Description: The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
Study NCT06333561 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic arterial infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
Study NCT06333561 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: 12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Study NCT05481333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Ascending IV or SC dose administered per protocol
Study NCT06333561 — intervention group
Intervention type: DRUG
Intervention: Tislelizumab
Description: 200mg intravenously every 3 weeks
Study NCT06333561 — intervention group
Intervention type: DRUG
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study NCT06333561 — intervention group
Intervention type: DRUG
Intervention: Sintilimab
Description: 200mg intravenously every 3 weeks
Study NCT06333561 — intervention group
Intervention type: DRUG
Intervention: Camrelizumab
Description: 200mg intravenously every 3 weeks
Study NCT05460962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises +and progressive muscle relaxation techniques
Description: Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
Study NCT05509959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women SHINE
Description: Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
Study NCT05509959 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Single group session and access to website
Study NCT04625673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OsciPulse
Description: OsciPulse device and standard IPC device
Study NCT05484141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation with blood blow restriction
Description: The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
Study NCT05484141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation without blood flow restriction
Description: The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
Study NCT05103449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Coaching
Description: Video-based coaching sessions after salpingectomy 1 and 2
Study NCT06532409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA
Description: Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
Study NCT06532409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV ceftriaxone
Description: Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
Study NCT05520112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
Description: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
Study NCT05520112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
Study NCT05520112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
Study NCT06557707 — intervention group
Intervention type: OTHER
Intervention: Childhood stress
Description: Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.
Study NCT04153942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Any movement out of bed
Study NCT04153942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: Any movement out of bed
Study NCT04664192 — intervention group
Intervention type: OTHER
Intervention: Patient Biospecimen Registry (observational and blood sampling)
Description: Clinical data collected at every blood sample collection visit.
Study NCT05481333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ascending IV or SC dose administered per protocol
Study NCT04347135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FES
Description: F-18 FES PET/MRI for detection of endometriosis.
Study NCT06116812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the laughter yoga group
Description: They will gather in five-person chemotherapy rooms, and laughter therapy will be applied to the women in the application group while they are receiving chemotherapy. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again.
Study NCT06116812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the mindfulness based stress reduction group
Description: Mindfulnes therapy will be applied to the women in the application group while they are receiving chemotherapy, in five-person chemotherapy rooms. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again.
Study NCT04034901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of cardiorespiratory parameters with BORA Band
Description: The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~* Activity~* Step count~* Heart rate~* Respiratory rate~* Skin temperature~* SpO2
Study NCT04769960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Studies
Description: MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
Study NCT04769960 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Reported Outcomes
Description: Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
Study NCT05443321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Information Exchange (HIE) platform
Description: An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
Study NCT05428748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 serving of test product
Description: Participants will consume 1 serving/day of the test product for 28 days
Study NCT06556069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-Support Enhanced Agitation Code Team (PACT)
Description: PACT will address systems challenges experienced by staff, safety threats to ED patients with mental illness and substance use disorders, and known structural biases against marginalized individuals during decisions in use of restraints for behavioral crises in the ED.~The PACT intervention includes a peer support service component to deliver patient-centered, trauma-informed, culturally sensitive care to patients presenting with behavioral complaints in the ED and experiencing distress.